Treatment of Cancers      

FOI REFERENCE: 24284  FOI DATE:  7^th August 2024     

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine		Number patients treated
1.1 Abemaciclib (Verzenios)		85
1.2 Alpelisib (Piqray)		0
1.3 Fulvestrant (fulvestrant or Faslodex)		33
1.4 Palbociclib (Ibrance)		83
1.5 Ribociclib (Kisqali)		6
1.6 Capivasertib (Truqap)		0

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Number patients treated

83

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Treatment intent		Number patients treated
3.1 Curative		75
3.2 Palliative		10
3.3 Not known / stated		Not applicable

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of combination or monotherapy		Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)		22
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)		15
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)		0

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of April 2024 and end of June 2024?

Type of breast cancer		Number patients treated
5.1 all types of breast cancer		6
5.2 adjuvant treatment for early breast cancer		6

PROSTATE CANCER

Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
6.1 Abiraterone (Zytiga or generic abiraterone)		44
6.2 Apalutamide (Erleada)		45
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)		9
6.4 Darolutamide (Nubeqa)		6
6.5 Enzalutamide (Xtandi)		175

Q7. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
Docetaxel for prostate cancer		0
Olaparib (Lynparza) for prostate cancer		0

Q8. How many patients were treated with the following medicine combinations in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
8.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy		0
8.2 Apalutamide (Erleada) + Androgen Deprivation Therapy		0
8.3 Darolutamide (Nubeqa) + Docetaxel + ADT		0
8.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy		0
8.5 Olaparib (Lynparza) + Abiraterone		0

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

OVARIAN and ENDOMETRIAL CANCERS

Q9. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
9.1 Dostarlimab (Jemperli)		0
9.2 Niraparib (Zejula)		11
9.3 Rucaparib (Rubraca)		5
9.4 Olaparib (Lynparza)		8

Q10. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
10.1 Olaparib in total		8
10.2 Olaparib monotherapy		8
10.3 Olaparib + bevacizumab in combination		12
10.4 Bevacizumab total		55
10.5 Bevacizumab monotherapy		8
10.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin		33